Longevity biotech is transitioning from high-concept science to early-stage clinical validation.
📈 What changed: 2026-08-26: Veeva Systems (VEEV) fiscal Q2 2027 results (quarter ended Jul 31) — total revenue $928.0M, +18% YoY; subscription $766.8M (+16%); non-GAAP operating margin 44.8%; non…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 15/100 | Very early — first human trials just beginning. |
| Evidence Strength higher is better · high confidence | 45/100 | Strong preclinical; human data sparse and early. |
| Commercial Proximity higher is better · medium confidence | 19/100 | Diagnostics near-term; therapeutics 5-10+ years. |
| Capital & Policy Support higher is better · low confidence | 26/100 | No dedicated longevity policy; FDA ageing-as-disease classification pending. |
| Crowding Risk lower is better · high confidence | 50/100 | Growing institutional and family office interest. |
| Reflexivity Risk lower is better · high confidence | 82/100 | Extremely high — celebrity-backed, narrative-driven, pre-revenue. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 17 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350+ themes and why, in your inbox. Free, no spam, one-click unsubscribe.